NCT06502548Recruiting
Endometriosis Transcriptomic Cell Atlas
Establishing an Endometriosis Transcriptomic Cell Atlas to Decipher the Pathophysiological Role of Stem Cells and Estrogens in the Disease
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
Endometriosis is an estrogen-dependent, chronic inflammatory gynecologic disease affecting women of reproductive age, with a therapeutic wandering of 6 to 10 years. A better understanding of the initiation phase is a major challenge to improve diagnosis and treatment. The most widely accepted hypothesis to explain the formation of endometriotic lesions is the tubal retrograde reflux during menstruation. However, only 10% of the reproductive age women will develop endometriosis while 90% of women experience retrograde menstruation. This raises the question of the stem cells present in the endometrium and menstrual reflux of these patients, but also of both the peritoneal microenvironment and the estrogenic local signaling which allow the implantation of these lesions.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- First submitted
- 28 Jun 2024
- Start date
- 27 Sept 2024
- Primary completion date
- Sept 2027
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Endometriosis
- NCT number
- NCT06502548
What you commit to
- Study type: Interventional
- Planned participants: 92
- From 27 Sept 2024 to the primary completion date, Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with endometriosis receiving hormonal treatment at the time of surgery or having received hormonal treatment in the 2 months prior to surgery
Other illness
- Healthy non-endometriotic patients undergoing hysterectomy for infectious or malignant causes
- Patients with positive serology for human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV), hepatitis B (HBV) and hepatitis C (HCV)
Other
- Patients with endometriosis non-surgically treated
- Patients with adenomyosis only
- Patients benefiting from a legal protection measure (guardianship, curatorship, safeguard of justice)
Who the study is looking for
- Patients over 18 and under 45 years of age
- Patients with multiple endometriosis sites (superficial, deep and endometriomas) with an indication for surgery to treat disabling painful symptoms and stage III or IV endometriosis in the context of infertility.
- Healthy patients including those operated on between the ages of 18 and 45 for tubal ligation
- Healthy patients operated on between the ages of 18 and 45 for hysterectomies for benign causes other than endometriosis or adenomyosis
- Patients operated on strictly at the time of menstruation
- Participants who have not been on hormonal treatment for 2 months
- Participant having signed the free and informed consent form
- Membership of a Social Security scheme or equivalent
Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital, Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.